199 related articles for article (PubMed ID: 37060423)
1. New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer.
Brett JO; Mayer EL
Curr Treat Options Oncol; 2023 Jun; 24(6):594-610. PubMed ID: 37060423
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
Rastogi P; O'Shaughnessy J; Martin M; Boyle F; Cortes J; Rugo HS; Goetz MP; Hamilton EP; Huang CS; Senkus E; Tryakin A; Cicin I; Testa L; Neven P; Huober J; Shao Z; Wei R; André V; Munoz M; San Antonio B; Shahir A; Harbeck N; Johnston S
J Clin Oncol; 2024 Mar; 42(9):987-993. PubMed ID: 38194616
[No Abstract] [Full Text] [Related]
3. Adjuvant Ovarian Function Suppression in Premenopausal Hormone Receptor-Positive Breast Cancer.
Basmadjian RB; Lupichuk S; Xu Y; Quan ML; Cheung WY; Brenner DR
JAMA Netw Open; 2024 Mar; 7(3):e242082. PubMed ID: 38477918
[TBL] [Abstract][Full Text] [Related]
4. Role of abemaciclib in primary breast cancer: a narrative review of MonarchE.
Takahashi N; Shimizu C; Shimomura A; Toi M
Transl Breast Cancer Res; 2022; 3():3. PubMed ID: 38751527
[TBL] [Abstract][Full Text] [Related]
5. Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
Goetz MP; Cicin I; Testa L; Tolaney SM; Huober J; Guarneri V; Johnston SRD; Martin M; Rastogi P; Harbeck N; Shahir A; Wei R; André V; Rugo HS; O'Shaughnessy J
NPJ Breast Cancer; 2024 Apr; 10(1):34. PubMed ID: 38671001
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.
Morganti S; Jin Q; Vincuilla J; Buehler R; Ryan S; Stokes S; Parker T; Mittendorf EA; King TA; Weiss A; Partridge AH; Bychkovsky BL; Curigliano G; Tayob N; Lin NU; Garber JE; Tolaney SM; Lynce F
NPJ Breast Cancer; 2024 Apr; 10(1):28. PubMed ID: 38627457
[TBL] [Abstract][Full Text] [Related]
7. Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India.
Parikh PM; Bhattacharyya GS; Biswas G; Krishnamurty A; Doval D; Heroor A; Sharma S; Deshpande R; Chaturvedi H; Somashekhar SP; Babu G; Reddy GK; Sarkar D; Desai C; Malhotra H; Rohagi N; Bapna A; Alurkar SS; Krishna P; Deo SVS; Shrivastava A; Chitalkar P; Majumdar SK; Vijay D; Thoke A; Udupa KS; Bajpai J; Rath GK; Dattatreya PS; Bondarde S; Patil S
South Asian J Cancer; 2021 Dec; 10(4):213-219. PubMed ID: 34984198
[TBL] [Abstract][Full Text] [Related]
8. Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives.
Varnier R; Sajous C; de Talhouet S; Smentek C; Péron J; You B; Reverdy T; Freyer G
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638325
[TBL] [Abstract][Full Text] [Related]
9. Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
J Clin Oncol; 2024 Apr; ():JCO2400711. PubMed ID: 38687953
[No Abstract] [Full Text] [Related]
10. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy
Slamon DJ; Fasching PA; Hurvitz S; Chia S; Crown J; Martín M; Barrios CH; Bardia A; Im SA; Yardley DA; Untch M; Huang CS; Stroyakovskiy D; Xu B; Moroose RL; Loi S; Visco F; Bee-Munteanu V; Afenjar K; Fresco R; Taran T; Chakravartty A; Zarate JP; Lteif A; Hortobagyi GN
Ther Adv Med Oncol; 2023; 15():17588359231178125. PubMed ID: 37275963
[TBL] [Abstract][Full Text] [Related]
11. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer.
Ye F; Dewanjee S; Li Y; Jha NK; Chen ZS; Kumar A; Vishakha ; Behl T; Jha SK; Tang H
Mol Cancer; 2023 Jul; 22(1):105. PubMed ID: 37415164
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.
Martín M; Carrasco E; Rodríguez-Lescure Á; Andrés R; Servitja S; Antón A; Ruiz-Borrego M; Bermejo B; Guerrero Á; Ramos M; Santaballa A; Muñoz M; Cruz J; Lopez-Tarruella S; Chacón JI; Álvarez I; Martínez P; Miralles JJ; Polonio Ó; Jara C; Aguiar-Bujanda D
Breast Cancer Res Treat; 2023 Sep; 201(2):151-159. PubMed ID: 37338729
[TBL] [Abstract][Full Text] [Related]
13. The MonarchE trial: improving the clinical outcome in HR
Bertucci F; Finetti P; Mamessier E; De Nonneville A
Cancer Commun (Lond); 2023 Aug; 43(8):938-942. PubMed ID: 37462449
[No Abstract] [Full Text] [Related]
14. Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer.
Curigliano G; Dent R; Llombart-Cussac A; Pegram M; Pusztai L; Turner N; Viale G
NPJ Breast Cancer; 2023 Jun; 9(1):56. PubMed ID: 37380659
[TBL] [Abstract][Full Text] [Related]
15. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review.
Zhao M; Hanson KA; Zhang Y; Zhou A; Cha-Silva AS
Target Oncol; 2023 May; 18(3):327-358. PubMed ID: 37074594
[TBL] [Abstract][Full Text] [Related]
16. "Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?".
Höller A; Nguyen-Sträuli BD; Frauchiger-Heuer H; Ring A
Breast Cancer (Dove Med Press); 2023; 15():525-540. PubMed ID: 37533589
[TBL] [Abstract][Full Text] [Related]
17. Implications of inflammatory cell death-related IFNG and co-expressed RNAs (AC006369.1 and CCR7) in breast carcinoma prognosis, and anti-tumor immunity.
Deng Y; Li Z; Pan M; Wu H; Ni B; Han X
Front Genet; 2023; 14():1112251. PubMed ID: 37408777
[No Abstract] [Full Text] [Related]
18. Progress and prospects in research and clinical practice of hormone receptor-positive, HER-2-negative breast cancer with BRCA1/2 mutations.
Yan S; Imam M
Discov Oncol; 2023 Jun; 14(1):110. PubMed ID: 37351713
[TBL] [Abstract][Full Text] [Related]
19. The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus.
Kaidar-Person O; Pfob A; Gentilini OD; Borisch B; Bosch A; Cardoso MJ; Curigliano G; De Boniface J; Denkert C; Hauser N; Heil J; Knauer M; Kühn T; Lee HB; Loibl S; Mannhart M; Meattini I; Montagna G; Pinker K; Poulakaki F; Rubio IT; Sager P; Steyerova P; Tausch C; Tramm T; Vrancken Peeters MJ; Wyld L; Yu JH; Weber WP; Poortmans P; Dubsky P
EClinicalMedicine; 2023 Jul; 61():102085. PubMed ID: 37528842
[TBL] [Abstract][Full Text] [Related]
20. Effect of HER2 expression status on the prognosis of patients with HR
Wang K; Du Q; Yu J; Li Y; Zhu X
Oncol Lett; 2023 Jul; 26(1):299. PubMed ID: 37323815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
